Ming-Tseh Lin

Ming-Tseh Lin

Auto-generated profile, based on publicly available information

Ming-Tseh Lin

From the Departments of Pathology (Drs De Marchi, Ibrahim, Zheng, Gocke, Eshleman, Belchis, Illei, and Lin, Ms Haley, Mr Fryer, and Ms Beierl) and Oncology (Drs Gocke and Eshleman), Johns Hopkins University School of Medicine, Baltimore, Maryland; and the Division of Hematology and Bone Marrow Transplantation, Hospital-University of Udine, Udine, Italy (Dr De Marchi)

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GZGang Zheng
Gang Zheng
LTLi-Hui Tseng
Li-Hui Tseng
GCGuoli Chen
Guoli Chen
LHLisa Haley
Lisa Haley
PIPeter Illei
Peter Illei
MLMing-Tseh Lin
Ming-Tseh Lin
Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been approved for treatment of metastatic melanomas with a BRAF p.V600E mutation. The clinical significance of non-codon 600 mutations remains unclear, in part, due to variation of kinase activity for different mutants. In this study, we categorized BRAF mutations according to the reported mutant kinase activity. A total of 1027 lung cancer, colorectal cancer or melanoma specimens were submitted for clinical mutation detection by next generation sequencing. Non-codon 600 mutations were observed in 37 % of BRAF-mutated tumors. Of all BRAF mutants, 75 % were kinase-activated, 15 % kinase-impaired and 10 % kinase-unknown. The most common kinase-impaired mutant involves codon 594, specifically, p.D594G (c.1781A > G) and p.D594N (c.1780G > A). Lung cancers showed significantly higher incidences of kinase-impaired or kinase-unknown mutants. Kinase-impaired BRAF mutants showed a significant association with concomitant activating KRAS or NRAS mutations, but not PIK3CA mutations, supporting the reported interaction of these mutations. BRAF mutants with impaired or unknown kinase activity as well as concomitant kinase-impaired BRAF mutations and RAS mutations were detected in lung cancers, colorectal cancers and melanomas. Different therapeutic strategies based on the BRAF mutant kinase activity and the concomitant mutations may be worthwhile.

5 July 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PLParvez M. Lokhandwala
Parvez M. Lokhandwala
LTLi-Hui Tseng
Li-Hui Tseng
ERErika Rodriguez
Erika Rodriguez
GZGang Zheng
Gang Zheng
APAparna Pallavajjalla
Aparna Pallavajjalla
MLMing-Tseh Lin
Ming-Tseh Lin
Analysis of melanomas for actionable mutations has become the standard of care. Recently, a classification scheme has been proposed that categorizes BRAF mutations based on their mechanisms for activation of the MAPK pathway. In this analysis BRAF, KIT, NRAS, and PIK3CA mutations were examined by next generation sequencing (NGS) in 446 melanomas in a clinical diagnostic setting. KRAS and HRAS were also analyzed to elucidate coexisting BRAF and RAS mutations. BRAF mutations were categorized into class-1 (kinase-activated, codon 600), class-2 (kinase-activated, non-codon 600) and class-3 (kinase-impaired), based on the newly proposed classification scheme. NGS demonstrated high analytic sensitivity. Among 355 mutations detected, variant allele frequencies were 2–5% in 21 (5.9%) mutations and 2–10% in 47 (13%) mutations. Mutations were detected in BRAF (42%), NRAS (25%), KIT (4.9%) and PIK3CA (2.7%). The incidence of class-1, class-2 and class-3 mutations were 33% (26% p.V600E and 6.1% p.V600K), 3.1 and 4.9% respectively. With a broader reportable range of NGS, class-1, class-2 and class-3 mutations accounted for 77, 7.4 and 12% of all BRAF mutations. Class-3 mutations, commonly affecting codons 594, 466 and 467, showed a higher incidence of coexisting RAS mutations, consistent with their RAS-dependent signaling. Significant association with old age and primary tumors of head/neck/upper back suggest chronic solar damage as a contributing factor for melanomas harboring BRAF p.V600K or class-3 mutations. This study categorizes the range, frequency, coexisting driver mutations and clinical characteristics of the three classes of BRAF mutations in a large cohort of melanomas in a clinical diagnostic setting. Further prospective studies are warranted to elucidate the clinical outcomes and benefits of newly developed targeted therapy in melanoma patients carrying each class of BRAF mutation.

31 July 2015 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
LHLisa Haley
Lisa Haley
LTLi-Hui Tseng
Li-Hui Tseng
GZGang Zheng
Gang Zheng
JDJonathan Dudley
Jonathan Dudley
DADerek A Anderson
Derek A Anderson
MLMing-Tseh Lin
Ming-Tseh Lin
Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers. We present performance characteristics of a next-generation sequencing assay designed to detect such mutations. In this retrospective quality assessment study, we analyzed mutation detected in the KRAS, NRAS, BRAF, and PIK3CA genes by a clinically validated next-generation sequencing assay in 310 colorectal cancer specimens. Tumor cellularity and mutant allele frequency were analyzed to identify tumor heterogeneity and mutant allele-specific imbalance. Next-generation sequencing showed precise measurement of mutant allele frequencies and detected 23% of mutations with 2–20% mutant allele frequencies. Of the KRAS mutations detected, 17% were outside of codons 12 and 13. Among PIK3CA mutations, 48% were outside of codons 542, 545, and 1047. The percentage of tumors with predicted resistance to anti-EGFR therapy increased from 40% when testing for only mutations in KRAS exon 2 to 47% when testing for KRAS exons 2–4, 48% when testing for KRAS and NRAS exons 2–4, 58% when including BRAF codon 600 mutations, and 59% when adding PIK3CA exon 20 mutations. Right-sided colorectal cancers carried a higher risk of predicted anti-EGFR resistance. A concomitant KRAS mutation was detected in 51% of PIK3CA, 23% of NRAS, and 33% of kinase-impaired BRAF-mutated tumors. Lower than expected mutant allele frequency indicated tumor heterogeneity, while higher than expected mutant allele frequency indicated mutant allele-specific imbalance. Two paired neuroendocrine carcinomas and adjacent adenomas showed identical KRAS mutations, but only PIK3CA mutations in neuroendocrine carcinomas. Next-generation sequencing is a robust tool for mutation detection in clinical laboratories. It demonstrates high analytic sensitivity and broad reportable range, and it provides simultaneous detection of concomitant mutations and a quantitative measurement of mutant allele frequencies to predict tumor heterogeneity and mutant allele-specific imbalance.

1 October 2015 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
JCJamal Carter
Jamal Carter
LTLi-Hui Tseng
Li-Hui Tseng
GZGang Zheng
Gang Zheng
JDJonathan Dudley
Jonathan Dudley
PIPeter Illei
Peter Illei
MLMing-Tseh Lin
Ming-Tseh Lin
Objectives:. To assess the performance of a next-generation sequencing (NGS) platform for the clinical detection of BRAF mutations.Methods:. In this r

7 March 2014 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
JDJonathan C. Dudley
Jonathan C. Dudley
GGGrzegorz T. Gurda
Grzegorz T. Gurda
LTLi-Hui Tseng
Li-Hui Tseng
DADerek A. Anderson
Derek A. Anderson
GCGuoli Chen
Guoli Chen
MLMing-Tseh Lin
Ming-Tseh Lin

4 July 2018 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
DPDoreen N. Palsgrove
Doreen N. Palsgrove
JBJacqueline A. Brosnan-Cashman
Jacqueline A. Brosnan-Cashman
CGCaterina Giannini
Caterina Giannini
ARAditya Raghunathan
Aditya Raghunathan
MJMark Jentoft
Mark Jentoft
FRFausto Rodriguez
Fausto Rodriguez